35 participants
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-06-25
- Start Date:
- 2026-06-01
- Completion:
- 2027-12-31
Conditions
- Ovary Cancer
Interventions
- DRUG
No Results Yet